FDA Approves Oral Daprodustat to Treat Anemia in Dialysis
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
Diagnosis & Disease Information
In Diabetes, Women Have Higher Risk for Venous Thromboembolism
Significantly higher association between diabetes and VTE seen among women versus men, especially those aged 50 to 59 years
Apixaban Compared With Dalteparin in Cancer-Related Venous Thromboembolism
Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.
Postop CV Morbidity Down With Increased Time From COVID-19 to Surgery
Odds of major postoperative cardiovascular morbidity reduced with increased time from COVID-19 diagnosis to surgery
Cardiovascular Events Up for Individuals Hospitalized With COVID-19
Largest effect sizes seen for venous thromboembolism, heart failure, and stroke; risks highest in first 30 days
Risk of Future Cardiovascular Events Stratified by COVID-19 Severity
A study was conducted to determine the relationship between COVID-19 severity and risk for cardiovascular events 30 days following diagnosis.
Interventions Can Improve Administration of VTE Prophylaxis
Improvement seen with electronic alert-triggered, patient-centered education bundle intervention or nurse feedback intervention
Risk for First-Time Clot Events Raised After COVID-19 Diagnosis
Incidence is highest in first week, but remains elevated up to 49 weeks after COVID-19 diagnosis
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
VTE Risk Higher With Arteriovenous Grafts vs Fistulas
The increased risk for venous thromboembolism with an arteriovenous graft is one factor for clinicians and patients to consider in the choice of vascular access for hemodialysis.
- Loading...
Loading...
Next post in Hemodialysis
Loading... 
Loading...